Genentech

VABYSMO

  1. Home
  2.  / 
  3. J Code
  4.  / VABYSMO – J2777

Manufacturer:

Genentech

Name:

VABYSMO

HCPCS Code Descriptor:

Injection, faricimab-svoa, 0.1 mg

Category:

J Code

HCPCS:

J2777

NDC(s):

50242-0096-01

Primary Type:

Opthalmic

Generic Status:

Single-Source

Route of Administration:

Intraocular

About:

VABYSMO is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2777 is aligned to the drug VABYSMO.

Vabysmo belongs to the class of drugs known as anti-angiogenic ophthalmic agents. Vabysmo is used to treat certain eye disorders and works by stopping two disease pathways in the eye that are thought to cause instability. Vabysmo is a branded drug manufactured by Genentech USA. From July 2022 to September 2022, Vabysmo was aligned to the C Code: C9097. Beginning in October 2022, Vabysmo has been aligned to the J Code: J2777. Patient assistance programs for this medication can be found through Genentech.

Access Pricing and More By Registering

HCPCS Added Date:

10/1/22

HCPCS Effective Date:

10/1/22

HCPCS Short Description:

Inj, faricimab-svoa, 0.1mg

Billing and Coding Guide:

https://www.genentech-access.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf

Patient Assistance:

https://www.gene.com/patients/patient-foundation/apply-for-help#patients

VABYSMO – J2777